Isavuconazonium

Brand names: Cresemba · Active ingredient: Isavuconazonium Sulfate

In short: CRESEMBA ® is indicated for the treatment of invasive aspergillosis as follows: CRESEMBA for injection: adults and pediatric patients 1 year of age and older CRESEMBA capsules: adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater [see Dosage and Administrati

Forms & strengthsCRESEMBA Capsules CRESEMBA 74.5 mg isavuconazonium sulfate (equivalent to 40 mg of isavuconazole) capsules are opaque and have a Swedish orange (reddish-brown) body imprinted with the Astellas logo in black ink and a Swedish orange cap imprinted with “557” in …
LabelAstellas Pharma US, Inc.
Label updatedMay 05, 2025

What is Isavuconazonium used for?

CRESEMBA

®

is indicated for the treatment of invasive aspergillosis as follows:

CRESEMBA for injection: adults and pediatric patients 1 year of age and older

CRESEMBA capsules: adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater [see

Dosage and Administration

(2.3) Clinical Studies (

14.1

) and Clinical Pharmacology (12.4)]

CRESEMBA is indicated for the treatment of invasive mucormycosis as follows:

CRESEMBA for injection: adults and pediatric patients 1 year of age and older

CRESEMBA capsules: adults and pediatric patients 6 years of age and older who weigh 16 kg and greater , Clinical Studies (14.1) and Clinical Pharmacology (12.3, 12.4)]

Specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s) should be obtained prior to initiating antifungal therapy. Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.

Isavuconazonium dosage

CRESEMBA for Injection

•CRESEMBA for injection is intended for use in patients who are 1 year of age and older .

•Intravenous formulation must be administered via an infusion set with an in-line filter (pore size 0.2 to 1.2 micron).

•Infuse the intravenous formulation over a minimum of 1 hour in 250 mL of a compatible diluent, to reduce the risk for infusion-related reactions. Do not administer as an intravenous bolus injection.

•Do not infuse CRESEMBA with other intravenous medications.

•Flush intravenous lines with 0.9% sodium chloride injection, USP or 5% dextrose injection, USP prior to and after infusion of CRESEMBA.

•After dilution of the intravenous formulation, avoid unnecessary vibration or vigorous shaking of the solution. Do not use a pneumatic transport system.

Nasogastric Tube Administration of CRESEMBA for Injection

•CRESEMBA for injection via nasogastric (NG) tube administration is intended for use by patients who are 6 years of age and older and weighing 16 kg and greater .

CRESEMBA Capsules

•CRESEMBA capsules are intended for use in patients who are 6 years of age and older and weighing 16 kg and greater .

•Switching between the intravenous and oral formulations of CRESEMBA is acceptable as bioequivalence has been demonstrated. Loading dose is not required when switching between formulations.

•With oral administration, swallow CRESEMBA capsules whole. Do not chew, crush, dissolve, or open the capsules. CRESEMBA capsules can be taken with or without food.

Recommended dosage and administration of CRESEMBA for injection and capsules in adult patients is described in Table 1 below. CRESEMBA (isavuconazonium sulfate) is the prodrug of isavuconazole, an azole antifungal drug.

Dosage Form | Loading Dose | Maintenance Dose

Start maintenance doses 12 to 24 hours after the last loading dose.

CRESEMBA for Injection, 372 mg/vial

372 mg372 mg of isavuconazonium sulfate is equivalent to 200 mg of isavuconazole. of isavuconazonium sulfate per vial | One reconstituted vial (372 mg)

intravenously

every 8 hours for 6 doses (48 hours) | One reconstituted vial (372 mg)

intravenously

once daily

CRESEMBA Capsules,

186 mg

186 mg186 mg of isavuconazonium sulfate is equivalent to 100 mg of isavuconazole. of isavuconazonium sulfate per capsule | Two 186 mg capsules (372 mg)

orally

every 8 hours for 6 doses (48 hours) | Two 186 mg capsules (372 mg)

orally

once daily

CRESEMBA Capsules, 74.5 mg

74.5 mg74.5 mg of isavuconazonium sulfate is equivalent to 40 mg of isavuconazole. …

How to take Isavuconazonium — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Important Administration Instructions

Advise patients that CRESEMBA can be taken with or without food. Each capsule should be swallowed whole. Do not chew, crush, dissolve, or open the capsules .

Drug Interactions

Advise patients to inform their physician if they are taking other drugs or before they begin taking other drugs as certain drugs can decrease or increase the plasma concentrations of CRESEMBA .

CRESEMBA can decrease or increase the plasma concentrations of other drugs .

Pregnancy

Advise patients to inform their physician if they are pregnant, plan to become pregnant, or are nursing .

Allergic Reactions

Advise patients to inform their physician immediately if they have ever had an allergic reaction to isavuconazole or other antifungal medicines such as ketoconazole, fluconazole, itraconazole, posaconazole, or voriconazole. Advise patients to discontinue CRESEMBA and seek immediate medical attention if any signs or symptoms of severe allergic reaction occur .

Marketed and Distributed by:Astellas Pharma US, Inc.Northbrook, IL 60062

CRESEMBA is a registered trademark of Astellas US LLC. …

Warnings & precautions

Do not take this medicine if: •CRESEMBA is contraindicated in persons with known hypersensitivity to isavuconazole.

•Coadministration of strong CYP3A4 inhibitors, such as ketoconazole or high-dose ritonavir (400 mg every 12 hours), with CRESEMBA is contraindicated because strong CYP3A4 inhibitors can significantly increase the plasma concentration of isavuconazole .

•Coadministration of strong CYP3A4 inducers, such as rifampin, carbamazepine, St. John’s wort, or long acting barbiturates with CRESEMBA is contraindicated because strong CYP3A4 inducers can significantly decrease the plasma concentration of isavuconazole .

•CRESEMBA shortened the QTc interval in a concentration-related manner. CRESEMBA is contraindicated in patients with familial short QT syndrome .

Hepatic adverse drug reactions (e.g., elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin) have been reported in clinical trials. The elevations in liver-related laboratory tests were generally reversible and did not require discontinuation of CRESEMBA. Cases of more severe hepatic adverse drug reactions including hepatitis, cholestasis or hepatic failure including death have been reported in patients with serious underlying medical conditions (e.g., hematologic malignancy) during treatment with azole antifungal agents, including CRESEMBA.

Evaluate liver-related laboratory tests at the start and during the course of CRESEMBA therapy. Monitor patients who develop abnormal liver-related laboratory tests during CRESEMBA therapy for the development of more severe hepatic injury. Discontinue CRESEMBA if clinical signs and symptoms consistent with liver disease develop that may be attributable to CRESEMBA . …

Isavuconazonium side effects

The following are discussed in more detail in other sections of the labeling:

•Hepatic Adverse Drug Reactions

•Infusion-Related Reactions

•Hypersensitivity Reactions

•Embryo-Fetal Toxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of CRESEMBA cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trials Experience in Adult Patients

A total of 403 adult patients were exposed to CRESEMBA in two clinical trials. The most frequently reported adverse reactions among CRESEMBA-treated patients were nausea (26%), vomiting (25%), diarrhea (22%), headache (17%), elevated liver chemistry tests (16%), hypokalemia (14%), constipation (13%), dyspnea (12%), cough (12%), peripheral edema (11%), and back pain (10%). Serious adverse reactions occurred in 223/403 (55%) of patients and 56/403 (14%) of patients permanently discontinued treatment with CRESEMBA due to an adverse reaction in the two trials. The adverse reactions which most often led to permanent discontinuation of CRESEMBA therapy during the clinical trials were confusional state (0.7%), acute renal failure (0.7%), increased blood bilirubin (0.5%), convulsion (0.5%), dyspnea (0.5%), epilepsy (0.5%), respiratory failure (0.5%), and vomiting (0.5%). …

Drug interactions

Isavuconazole is a sensitive substrate of CYP3A4. CYP3A4 inhibitors or inducers may alter the plasma concentrations of isavuconazole.

Isavuconazole is a moderate inhibitor of CYP3A4, and a mild inhibitor of P-glycoprotein (P-gp), and organic cation transporter 2 (OCT2).

Drug interaction studies were conducted to investigate the effect of coadministered drugs on the pharmacokinetics of isavuconazole and the effect of isavuconazole on the pharmacokinetics of coadministered drugs .

Recommendation | Comments

Ketoconazole | Contraindicate coadministration of all potent CYP3A4 inhibitors | There is more than a 5-fold increase in exposure of isavuconazole upon coadministration with ketoconazole

.

Lopinavir/ritonavir400 mg of lopinavir in combination with 100 mg of ritonavir. | Caution is advised when CRESEMBA is coadministered with lopinavir/ritonavir | There is a 96% increase in exposure of isavuconazole when coadministered with lopinavir/ritonavir

.

Rifampin | Contraindicate coadministration of all potent CYP3A4 inducers | There is a 97% decrease in exposure of isavuconazole upon coadministration with rifampin

.

Recommendation | Comments

Lopinavir/ritonavir400 mg of lopinavir in combination with 100 mg of ritonavir. …

About this medicine

CRESEMBA contains isavuconazonium sulfate, which is the prodrug of isavuconazole, an azole antifungal drug. Isavuconazonium sulfate drug substance is an amorphous, white to yellowish-white powder. The chemical name of isavuconazonium sulfate is glycine, N-methyl-, [2-[[[1-[1-[(2R,3R)-3-[4-(4-cyanophenyl)-2-thiazolyl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-4H-1,2,4-triazolium-4-yl]ethoxy]carbonyl]methylamino]-3-pyridinyl]methyl ester, sulfate (1:1). The empirical formula is C35H35F2N8O5S·HSO4, the molecular weight is 814.84 and the structural formula is:

CRESEMBA Capsules

CRESEMBA (isavuconazonium sulfate) 74.5 mg capsules are available for oral administration. Each CRESEMBA capsule contains 74.5 mg isavuconazonium sulfate, equivalent to 40 mg isavuconazole. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8f7f73b8-586a-4df0-935f-fecd4696c16c. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin